Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
4.030
-0.360 (-8.20%)
May 9, 2025, 1:12 PM - Market open
Scilex Holding Company Revenue
In the year 2024, Scilex Holding Company had annual revenue of $56.59M with 21.07% growth. Scilex Holding Company had revenue of $14.90M in the quarter ending December 31, 2024, with 10.68% growth.
Revenue (ttm)
$56.59M
Revenue Growth
+21.07%
P/S Ratio
0.29
Revenue / Employee
$492,087
Employees
115
Market Cap
21.10M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Abbott Laboratories | 42.34B |
SCLX News
- 8 days ago - Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. - GlobeNewsWire
- 8 days ago - Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewsWire
- 17 days ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 - GlobeNewsWire
- 22 days ago - Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - GlobeNewsWire
- 24 days ago - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada - GlobeNewsWire
- 4 weeks ago - Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - GlobeNewsWire
- 2 months ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 - GlobeNewsWire